Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

889 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.
Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schöffski P, Voest EE, Gomez-Roca C, Evans TR, Plummer R, Gallerani E, Kaye SB, Olmos D. Cassier PA, et al. Among authors: schellens jh. Ann Oncol. 2014 Jun;25(6):1222-8. doi: 10.1093/annonc/mdu108. Epub 2014 Mar 7. Ann Oncol. 2014. PMID: 24608201 Free article.
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.
Ploquin A, Olmos D, Lacombe D, A'Hern R, Duhamel A, Twelves C, Marsoni S, Morales-Barrera R, Soria JC, Verweij J, Voest EE, Schöffski P, Schellens JH, Kramar A, Kristeleit RS, Arkenau HT, Kaye SB, Penel N. Ploquin A, et al. Among authors: schellens jh. Br J Cancer. 2012 Sep 25;107(7):1025-30. doi: 10.1038/bjc.2012.371. Epub 2012 Aug 21. Br J Cancer. 2012. PMID: 22910320 Free PMC article.
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.
Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB. Olmos D, et al. Among authors: schellens jh. J Clin Oncol. 2012 Mar 20;30(9):996-1004. doi: 10.1200/JCO.2010.34.5074. Epub 2012 Feb 21. J Clin Oncol. 2012. PMID: 22355064
Topoisomerase I inhibition: a new target or new missiles?
Verweij J, Schellens JH. Verweij J, et al. Among authors: schellens jh. Ann Oncol. 1995 Feb;6(2):102-4. doi: 10.1093/oxfordjournals.annonc.a059100. Ann Oncol. 1995. PMID: 7786815 Free article. No abstract available.
Emerging drug treatments for solid tumours.
Schellens JH, Pronk LC, Verweij J. Schellens JH, et al. Drugs. 1996 Jan;51(1):45-72. doi: 10.2165/00003495-199651010-00005. Drugs. 1996. PMID: 8741232 Review.
Clinical research on antiangiogenic therapy.
Kuiper RA, Schellens JH, Blijham GH, Beijnen JH, Voest EE. Kuiper RA, et al. Among authors: schellens jh. Pharmacol Res. 1998 Jan;37(1):1-16. doi: 10.1006/phrs.1997.0268. Pharmacol Res. 1998. PMID: 9503474 Review.
Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models.
Vermaat JS, van der Tweel I, Mehra N, Sleijfer S, Haanen JB, Roodhart JM, Engwegen JY, Korse CM, Langenberg MH, Kruit W, Groenewegen G, Giles RH, Schellens JH, Beijnen JH, Voest EE. Vermaat JS, et al. Among authors: schellens jh. Ann Oncol. 2010 Jul;21(7):1472-1481. doi: 10.1093/annonc/mdp559. Epub 2009 Dec 18. Ann Oncol. 2010. PMID: 20022911 Free article.
889 results